4/A: Inari Medical Director Amends Form 4 Filing to Include Power of Attorney

Dana G. Mead, Jr., a director at Inari Medical, Inc., amended his Form 4 filing to include a Power of Attorney, related to restricted stock units.

Summary

• Dana G. Mead, Jr., a director of Inari Medical, Inc., filed an amended Form 4 with the SEC.
• The amendment, filed on May 31, 2024, updates the original Form 4 filed on April 26, 2024, to include a Power of Attorney.
• The original transaction reported was the acquisition of 4,126 shares of common stock on April 24, 2024, at a price of $42.41 per share, and the disposal of 11,148 shares.
• These shares were granted as restricted stock units, vesting fully on the earlier of the day prior to the company's next annual meeting or one year from the grant date.
• The Power of Attorney grants specific individuals the authority to act on Mead's behalf in matters related to SEC filings, including Forms 3, 4, 5, and 144.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders, such as directors and officers, across all publicly traded companies in the United States.
• The reporting requirements are governed by Section 16 of the Securities Exchange Act of 1934.
• Similar filings are made by insiders at companies like Medtronic, Boston Scientific, and Abbott Laboratories when they trade their company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The Power of Attorney ensures continued compliance with SEC regulations.

Key Dates